Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Bacillus Calmetteguérin Bcg

Research Leaders

5 sponsors active, led by The University of Western Australia

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT03246230Not ApplicableCompletedPrimary

Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity

Showing all 1 trials

Research Network

Common Treatments

  • Bacillus Calmetteguérin Bcg1
  • Hepatitis B Vaccine Hbv1

Active Sponsors

  • The University of Western Australia1
  • University of British Columbia1
  • Institute for Medical Research, Papua New Guinea1
  • Medical Research Council Unit, The Gambia1
  • Boston Children's Hospital1

Top Investigators

Activity Timeline